XML 27 R17.htm IDEA: XBRL DOCUMENT
v3.22.2.2

EARNINGS PER SHARE | 9 Months Ended
--- | ---
Sep. 30, 2022
EARNINGS PER SHARE |
EARNINGS PER SHARE | 11. EARNINGS PER SHARE The following represents the calculation of earnings (loss) per share (in thousands, except per share amounts): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | September 30, | ​ | September 30,
​ |  | 2022 | ​ | 2021 | ​ | 2022 | ​ | 2021
Basic: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income (loss) | ​ | $ | 105,888 | ​ | $ | 13,052 | ​ | $ | 26,191 | ​ | $ | (54,252)
Weighted average basic number of common shares outstanding | ​ | ​ | 16,340 | ​ | ​ | 16,270 | ​ | ​ | 16,327 | ​ | ​ | 16,257
Basic net income (loss) per share of common stock | ​ | $ | 6.48 | ​ | $ | 0.80 | ​ | $ | 1.60 | ​ | $ | (3.34)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Diluted: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income (loss) | ​ | $ | 105,888 | ​ | $ | 13,052 | ​ | $ | 26,191 | ​ | $ | (54,252)
Weighted average basic number of common shares outstanding | ​ | ​ | 16,340 | ​ | ​ | 16,270 | ​ | ​ | 16,327 | ​ | ​ | 16,257
Common stock equivalent shares representing shares issuable upon: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Exercise of Warrants & Stock Options | ​ | ​ | Anti-dilutive | ​ | ​ | Anti-dilutive | ​ | ​ | Anti-dilutive | ​ | ​ | Anti-dilutive
Vesting of restricted stock units | ​ | ​ | 143 | ​ | ​ | 158 | ​ | ​ | 169 | ​ | ​ | Anti-dilutive
Weighted average diluted number of common shares outstanding | ​ | ​ | 16,483 | ​ | ​ | 16,428 | ​ | ​ | 16,496 | ​ | ​ | 16,257
Diluted net income (loss) per share of common stock | ​ | $ | 6.42 | ​ | $ | 0.79 | ​ | $ | 1.59 | ​ | $ | (3.34)
​ Common stock equivalents, including warrants and options, totaling 7.4 million for the three and nine months ended September 30, 2022 and three months ended September 30, 2021 were anti-dilutive and not included in the computation of diluted earnings per share of common stock. For the nine months ended September 30, 2021, common stock equivalents, including warrants, options and restricted stock units, totaling 7.7 million were not included in the computation of diluted earnings per share of common stock because the effect would have been anti-dilutive due to the Company’s net loss in that period.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration